Lisa E. J. Douglas
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Lisa E. J. Douglas has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- James A. Reihill
School of Pharmacy, Queen's University Belfast, Belfast, UK
2 shared publications - S. Lorraine Martin
School of Pharmacy, Queen's University Belfast, Belfast, UK
2 shared publications James A Reihill
School of Pharmacy, Queen's University Belfast, Belfast, United Kingdom
1 shared publication- Mei Zhou
Natural Drug Discovery Group, School of Pharmacy, Queen’s University Belfast, Belfast BT9 7BL, UK
1 shared publication S Lorraine Martin
School of Pharmacy, Queen's University Belfast, Belfast, United Kingdom
1 shared publicationTatjana Odrljin
Boston Pharmaceuticals, Cambridge, MA, United States
1 shared publication
Latest Publications
- 9 September 2023
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 62 (suppl 67) , PA1868
Highly selective furin inhibition as a therapeutic approach for chronic obstructive pulmonary disease
Chronic obstructive pulmonary disease (COPD) is associated with two major clinical phenotypes; chronic bronchitis (CB) and emphysema. Impaired mucociliary clearance is a feature of CB which is influenced by Cl- secretion by the cystic fibrosis transmembrane conductance regulator (CFTR) and Na+ absorption by the epithelial sodium channel (ENaC). Furin, a cellular proprotein convertase, is a key proteolytic activator of ENaC. We have recently shown highly selective furin inhibition to inhibit ENaC and improve mucociliary transport (MCT) in cystic fibrosis (CF) airways cells (Douglas et al (2022) Cell Chem. Biol. 29(6):947-957). As mutated CFTR results in CF lung disease that shares phenotypic characteristics with CB, the aim of this study was to investigate the effect of a novel, highly potent, selective furin inhibitor, BOS-857 on ENaC activity and MCT in COPD. This study also aimed to determine whether BOS-857 used in combination with CFTR potentiator, ivacaftor would provide additional benefit. BOS-857 treatment of COPD HBECs significantly reduced ENaC-mediated Na+ absorption by 80% after a 48h exposure and prevented subsequent cell-surface activation of ENaC by neutrophil elastase. Treatment of COPD HBECs with either BOS-857 or VX-770 alone improved MCT rates. When COPD HBECs were treated with a combination of BOS-857 and VX-770, significant improvements in MCT rate over VX-770 alone were observed. These studies support highly selective furin inhibition as a therapeutic approach for COPD and suggest that further therapeutic benefit may also be derived by combining furin inhibition with a CFTR potentiator.
- 9 September 2023
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 62 (suppl 67) , PA1868
Highly selective furin inhibition as a therapeutic approach for chronic obstructive pulmonary disease
Chronic obstructive pulmonary disease (COPD) is associated with two major clinical phenotypes; chronic bronchitis (CB) and emphysema. Impaired mucociliary clearance is a feature of CB which is influenced by Cl- secretion by the cystic fibrosis transmembrane conductance regulator (CFTR) and Na+ absorption by the epithelial sodium channel (ENaC). Furin, a cellular proprotein convertase, is a key proteolytic activator of ENaC. We have recently shown highly selective furin inhibition to inhibit ENaC and improve mucociliary transport (MCT) in cystic fibrosis (CF) airways cells (Douglas et al (2022) Cell Chem. Biol. 29(6):947-957). As mutated CFTR results in CF lung disease that shares phenotypic characteristics with CB, the aim of this study was to investigate the effect of a novel, highly potent, selective furin inhibitor, BOS-857 on ENaC activity and MCT in COPD. This study also aimed to determine whether BOS-857 used in combination with CFTR potentiator, ivacaftor would provide additional benefit. BOS-857 treatment of COPD HBECs significantly reduced ENaC-mediated Na+ absorption by 80% after a 48h exposure and prevented subsequent cell-surface activation of ENaC by neutrophil elastase. Treatment of COPD HBECs with either BOS-857 or VX-770 alone improved MCT rates. When COPD HBECs were treated with a combination of BOS-857 and VX-770, significant improvements in MCT rate over VX-770 alone were observed. These studies support highly selective furin inhibition as a therapeutic approach for COPD and suggest that further therapeutic benefit may also be derived by combining furin inhibition with a CFTR potentiator.
- Open Access
Modulation of Ion Transport to Restore Airway Hydration in Cystic Fibrosis
Cystic fibrosis (CF) is a life-limiting genetic disorder caused by loss-of-function mutations in the gene which codes for the CF transmembrane conductance regulator (CFTR) Cl− channel. Loss of Cl− secretion across the apical membrane of airway lining epithelial cells results in dehydration of the airway surface liquid (ASL) layer which impairs mucociliary clearance (MCC), and as a consequence promotes bacterial infection and inflammation of the airways. Interventions that restore airway hydration are known to improve MCC. Here we review the ion channels present at the luminal surface of airway epithelial cells that may be targeted to improve airway hydration and MCC in CF airways.
Open AccessModulation of Ion Transport to Restore Airway Hydration in Cystic Fibrosis
Cystic fibrosis (CF) is a life-limiting genetic disorder caused by loss-of-function mutations in the gene which codes for the CF transmembrane conductance regulator (CFTR) Cl− channel. Loss of Cl− secretion across the apical membrane of airway lining epithelial cells results in dehydration of the airway surface liquid (ASL) layer which impairs mucociliary clearance (MCC), and as a consequence promotes bacterial infection and inflammation of the airways. Interventions that restore airway hydration are known to improve MCC. Here we review the ion channels present at the luminal surface of airway epithelial cells that may be targeted to improve airway hydration and MCC in CF airways.
- Open Access
- 28 March 2020
- Published by MDPI AG in Biomolecules
- Vol. 10 (4) , 515
A Novel Serine Protease Inhibitor PE-BBI Ameliorates Cockroach Extract-Mediated Airway Epithelial Barrier Dysfunction
Epithelial barrier dysfunction, characteristic of allergic airway disease may be, at least in part, due to the action of allergen-associated protease activities. Cockroach allergy is a major global health issue, with cockroaches containing considerable serine trypsin-like protease (TLP) activity. The present study sought to evaluate two novel protease inhibitors (PE-BBI and pLR-HL), recently isolated from amphibian skin secretions, for their potential to neutralise cockroach TLP activity and to determine any protective effect on cockroach-induced airway epithelial barrier disruption. Inhibitor potencies against the cockroach-associated activities were determined using a fluorogenic peptide substrate-based activity assay. 16HBE14o- cells (16HBE; a bronchial epithelial cell line) were treated with cockroach extract (CRE) in the presence or absence of the compounds in order to assess cell viability (RealTime Glo luminescent assay) and epithelial barrier disruption (transepithelial resistance and paracellular dextran flux). PE-BBI potently and selectively inhibited CRE TLP activity (pIC50 -8), but not host (16HBE) cell surface activity, which conferred protection of 16HBE cells from CRE-induced cell damage and barrier disruption. Novel protease inhibitor strategies such as PE-BBI may be useful for the treatment of allergic airway disease caused by cockroach proteases.
- 28 March 2020
- Published by MDPI AG in Biomolecules
- Vol. 10 (4) , 515
Open AccessA Novel Serine Protease Inhibitor PE-BBI Ameliorates Cockroach Extract-Mediated Airway Epithelial Barrier Dysfunction
Epithelial barrier dysfunction, characteristic of allergic airway disease may be, at least in part, due to the action of allergen-associated protease activities. Cockroach allergy is a major global health issue, with cockroaches containing considerable serine trypsin-like protease (TLP) activity. The present study sought to evaluate two novel protease inhibitors (PE-BBI and pLR-HL), recently isolated from amphibian skin secretions, for their potential to neutralise cockroach TLP activity and to determine any protective effect on cockroach-induced airway epithelial barrier disruption. Inhibitor potencies against the cockroach-associated activities were determined using a fluorogenic peptide substrate-based activity assay. 16HBE14o- cells (16HBE; a bronchial epithelial cell line) were treated with cockroach extract (CRE) in the presence or absence of the compounds in order to assess cell viability (RealTime Glo luminescent assay) and epithelial barrier disruption (transepithelial resistance and paracellular dextran flux). PE-BBI potently and selectively inhibited CRE TLP activity (pIC50 -8), but not host (16HBE) cell surface activity, which conferred protection of 16HBE cells from CRE-induced cell damage and barrier disruption. Novel protease inhibitor strategies such as PE-BBI may be useful for the treatment of allergic airway disease caused by cockroach proteases.